J P Morgan Chase & Co Increases Davita (DVA) Price Target to $84.00
Several other research firms have also commented on DVA. SunTrust Banks set a $70.00 price target on Davita and gave the stock a hold rating in a report on Thursday. Raymond James Financial upgraded Davita from an outperform rating to a strong-buy rating and lifted their price target for the stock from $65.00 to $84.00 in a report on Thursday. KeyCorp reiterated a hold rating on shares of Davita in a report on Wednesday, December 6th. Wolfe Research upgraded shares of Davita from a market perform rating to an outperform rating in a report on Monday, October 23rd. Finally, Royal Bank Of Canada reduced their price objective on shares of Davita from $64.00 to $60.00 and set a sector perform rating on the stock in a report on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. Davita currently has a consensus rating of Hold and a consensus target price of $69.88.
Davita (NYSE DVA) opened at $67.71 on Thursday. Davita has a fifty-two week low of $52.51 and a fifty-two week high of $70.16. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. The company has a market capitalization of $12,410.00, a price-to-earnings ratio of 19.35, a PEG ratio of 13.65 and a beta of 0.97.
Davita announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.
A number of institutional investors and hedge funds have recently modified their holdings of DVA. Rhumbline Advisers grew its position in Davita by 4.4% in the 3rd quarter. Rhumbline Advisers now owns 321,155 shares of the company’s stock valued at $19,073,000 after acquiring an additional 13,471 shares in the last quarter. Riverhead Capital Management LLC grew its position in Davita by 10.6% in the 2nd quarter. Riverhead Capital Management LLC now owns 112,506 shares of the company’s stock valued at $7,286,000 after acquiring an additional 10,775 shares in the last quarter. Founders Capital Management LLC grew its position in Davita by 2.3% in the 3rd quarter. Founders Capital Management LLC now owns 95,939 shares of the company’s stock valued at $5,698,000 after acquiring an additional 2,115 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its position in Davita by 1,987.3% in the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock valued at $2,448,000 after acquiring an additional 39,746 shares in the last quarter. Finally, Speece Thorson Capital Group Inc. grew its position in Davita by 14.5% in the 3rd quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock valued at $19,075,000 after acquiring an additional 40,667 shares in the last quarter. Hedge funds and other institutional investors own 85.32% of the company’s stock.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita Inc and related companies with MarketBeat.com's FREE daily email newsletter.